Avalo Therapeutics, Inc. (AVTX)
Largest Insider Buys in Sector
AVTX Stock Price History Chart
AVTX Stock Performance
About Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 …
Insider Activity of Avalo Therapeutics, Inc.
Over the last 12 months, insiders at Avalo Therapeutics, Inc. have bought $12,750 and sold $0 worth of Avalo Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Avalo Therapeutics, Inc. have bought $8.11M and sold $2.17M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Almenoff June Sherie (director) — $25,499.
The last purchase of 500 shares for transaction amount of $6,500 was made by Almenoff June Sherie (director) on 2024‑11‑13.
List of Insider Buy and Sell Transactions, Avalo Therapeutics, Inc.
| 2024-11-13 | director | 500 0.4267% | $13.00 | $6,500 | -26.49% | |||
| 2024-11-12 | director | 500 0.4103% | $12.50 | $6,250 | -22.68% | |||
| 2023-06-27 | Sale | 10 percent owner | 937,404 9.668% | $0.52 | $486,888 | -85.36% | ||
| 2023-06-26 | Sale | 10 percent owner | 2.75M 28.7234% | $0.61 | $1.68M | -87.33% | ||
| 2023-06-26 | 10 percent owner | 1.61M 17.5933% | $0.64 | $1.03M | -87.33% | |||
| 2023-06-20 | 10 percent owner | 2,000 0.0174% | $4.14 | $8,289 | -98.40% | |||
| 2023-06-16 | 10 percent owner | 3,000 0.0255% | $3.90 | $11,714 | -98.31% | |||
| 2023-06-15 | 10 percent owner | 3,160 0.0264% | $3.68 | $11,640 | -98.24% | |||
| 2023-06-14 | 10 percent owner | 6,000 0.0586% | $3.48 | $20,874 | -97.81% | |||
| 2023-06-13 | 10 percent owner | 8,750 0.0772% | $3.82 | $33,439 | -98.19% | |||
| 2023-06-12 | 10 percent owner | 2,149 0.0193% | $4.34 | $9,316 | -98.37% | |||
| 2023-06-09 | 10 percent owner | 5,044 0.0444% | $4.14 | $20,896 | -98.30% | |||
| 2023-06-09 | CEO and Chairman of the Board | 4,000 0.0291% | $3.42 | $13,680 | -98.30% | |||
| 2023-06-09 | Chief Financial Officer | 511 0.0037% | $3.42 | $1,748 | -98.30% | |||
| 2023-06-08 | 10 percent owner | 6,398 0.0517% | $3.93 | $25,126 | -98.35% | |||
| 2023-06-07 | 10 percent owner | 2,984 0.0229% | $3.49 | $10,418 | -98.22% | |||
| 2023-05-31 | 10 percent owner | 844 0.0072% | $2.87 | $2,422 | -97.06% | |||
| 2023-05-30 | 10 percent owner | 671 0.0057% | $2.87 | $1,924 | -97.04% | |||
| 2023-05-25 | 10 percent owner | 2,000 0.0179% | $2.77 | $5,540 | -96.68% | |||
| 2023-05-24 | 10 percent owner | 9,000 0.0792% | $2.98 | $26,816 | -96.94% |
Insider Historical Profitability
| Almenoff June Sherie | director | 1000 0.0096% | $8.81 | 2 | 0 | |
| Boyd Steven | 47576000 454.681% | $8.81 | 2 | 0 | ||
| Ball Gary Edward | President | 15500000 148.1326% | $8.81 | 1 | 0 | |
| Moscato Robert Jr. | COO | 2592743 24.7787% | $8.81 | 1 | 0 | |
| ARMISTICE CAPITAL, LLC | 10 percent owner | 731458 6.9905% | $8.81 | 164 | 2 |